Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-MDD-2 Brenipatide Adjunctive Phase 3 Relapse Prevention Study
2025-522310-24-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Brenipatide adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Time to relapse of major depressive disorder. Planned start Sep 2026; status: authorised.
02
Drugs
brenipatide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-522310-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522310-24-00.